Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the April 13, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought shares during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 13, 2026, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the design of its Pivotal Study for a drug candidate related to Huntington's Disease, including FDA approval status [4] - It is claimed that uniQure downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies [4] - The lawsuit asserts that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true details emerged [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed information related to the company's Pivotal Study and BLA submission timeline [2][4]. Group 1: Allegations and Legal Actions - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA submission for AMT-130 [4]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would support a BLA submission, contradicting previous representations about the approval timeline [5]. - Following this disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [6]. Group 2: Investor Information - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - There is an April 13, 2026, deadline for investors to seek the role of lead plaintiff in the federal securities class action against uniQure [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. for allegedly misleading investors regarding its Huntington's disease gene therapy drug AMT-130 during the class period from September 24, 2025, to October 31, 2025 [1][2] Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1] - Investors who purchased uniQure ordinary shares during the class period may seek to serve as lead plaintiff by April 13, 2026 [1] Allegations - The complaint alleges that uniQure made materially false and misleading statements about its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [1] - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its BLA submission [1] Impact on Share Price - On November 3, 2025, uniQure's share price dropped by $33.40, or over 49%, from $67.69 to $34.29 per share after the company disclosed that the FDA did not agree that the data from the Phase I/II studies was adequate for BLA submission [1] Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing to be lead plaintiff by the deadline [1] - The lead plaintiff process allows investors to represent the class in litigation, with the potential for recovery not affected by the decision to serve as lead plaintiff [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to allegations of violations of federal securities laws, particularly concerning misleading statements related to the company's Pivotal Study and its implications for the BLA submission timeline [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA submission for AMT-130 [5]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would support a BLA submission, contradicting previous statements about the path toward accelerated approval [6]. - Following this disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [7]. Group 2: Class Action Details - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to discuss their legal rights and consider seeking the role of lead plaintiff in the class action [3][8]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi encourages anyone with information regarding uniQure's conduct to come forward, including whistleblowers and former employees [9].

Core Viewpoint - Investors are increasingly concerned about the future of experimental drugs for hard-to-treat diseases due to recent rejections by the U.S. Food and Drug Administration (FDA) [1][4]. Group 1: FDA Rejections and Investor Sentiment - The FDA has denied or discouraged applications for at least eight drugs in the past year, including gene therapies for Huntington's disease and Hunter syndrome, as well as a drug for a blood condition [2]. - The FDA's rejections stem from issues with the evidence provided by companies, such as the lack of placebo-controlled studies and reliance on biomarkers instead of direct efficacy measurements [3]. - Companies have accused the FDA of reversing previous guidance, leading to investor wariness about the agency's unpredictability and its impact on future treatments [4]. Group 2: Regulatory Standards and Implications - Historically, the FDA was more lenient with drugs for rare diseases, allowing approvals based on less rigorous studies, which has drawn both support and criticism [5]. - The recent decisions have raised questions about whether the FDA's standards have changed for other drugs in development, as seen with UniQure being asked to conduct a new placebo-controlled study [6]. - Analysts are monitoring several companies, including Dyne Therapeutics and Taysha Gene Therapies, whose stock prices have declined this year amid regulatory uncertainty [8]. Group 3: Company Responses and Future Outlook - Dyne Therapeutics expressed confidence in its development strategy and ongoing dialogue with the FDA, while other companies like Taysha, Wave, and Lexeo declined to comment [9]. - Denali Therapeutics is awaiting a decision on its drug candidate for Hunter syndrome, with the FDA delaying its review by three months, now expected by April 5 [12]. - Some investors perceive a disconnect between the FDA's public commitments to flexibility and its recent decisions, leading to skepticism about the success of companies relying on flexible data acceptance [13]. Group 4: FDA's Position on Data Requirements - A senior FDA official stated that the agency's stance on using biomarkers for accelerated approval remains unchanged, and non-randomized data can still lead to full approval [15]. - The official emphasized that significant improvements in severely ill patients could warrant full regulatory approval even with limited data [16]. - The FDA requires randomized data primarily in cases where conditions are heterogeneous or when the potential for misleading results is high [17].

Core Viewpoint - Shares of uniQure N.V. (QURE) dropped 31.8% in a week due to a disappointing regulatory update regarding its gene therapy AMT-130 for Huntington's disease [1] Regulatory Update - uniQure received final meeting minutes from the FDA after a Type A meeting on January 30, 2026, indicating that the data from ongoing phase I/II studies are insufficient to support a marketing application [2] - The FDA strongly recommended a prospective, randomized, double-blind study with a sham surgery control to adequately evaluate AMT-130's efficacy [3] Company Strategy - Management believes that the existing data justifies continued engagement with the FDA despite not reaching alignment on a regulatory submission strategy [4] - uniQure plans to request a Type B meeting in Q2 2026 to explore study design options and clarify the regulatory pathway for AMT-130 [3] Clinical Data - High-dose AMT-130 reportedly slowed Huntington's disease progression by 75% after three years, with patients showing decreased levels of a key biomarker linked to neurodegeneration [6][5] - Prior to the recent regulatory feedback, uniQure had reported meeting key goals in the phase I/II study of AMT-130 [6][7] Other Developmental Programs - uniQure's clinical pipeline includes candidates for refractory mesial temporal lobe epilepsy, amyotrophic lateral sclerosis, and Fabry disease [9] - The company also markets a gene therapy for hemophilia B in partnership with CSL Behring under the brand name Hemgenix [10] Market Context - Over the past six months, QURE shares have declined by 38.9%, contrasting with the industry's growth of 19.6% [4]

Core Viewpoint - Federal health officials are facing criticism for rejecting rare-disease drugs, specifically targeting an Amsterdam-based biotech company that is seeking approval for a Huntington's disease treatment [1] Group 1 - Federal health officials have been criticized by lawmakers for their recent decisions regarding the approval of drugs for rare diseases [1] - The focus of the criticism is on a biotech company based in Amsterdam that is attempting to gain approval for a treatment aimed at Huntington's disease [1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. due to allegations of securities fraud and unlawful business practices, following a significant drop in stock price after negative feedback from the FDA regarding its investigational gene therapy AMT-130 [1][1][1] Company Summary - uniQure N.V. is facing a class action lawsuit related to potential securities fraud involving its officers and directors [1] - The lawsuit is prompted by a press release from November 3, 2025, where uniQure announced that the FDA no longer believes that data from Phase I/II studies of AMT-130 may be adequate for a Biologics License Application (BLA) submission [1][1] - Following this announcement, uniQure's stock price fell by $33.40 per share, or 49.34%, closing at $34.29 per share [1][1][1] Industry Context - Pomerantz LLP, the law firm handling the class action, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [1][1]

Core Viewpoint - UniQure is required by the FDA to conduct another study to demonstrate the efficacy of its gene therapy for Huntington's disease, amidst ongoing disputes regarding the ethical implications of such a trial [1][2][3] Group 1: FDA's Position - A senior FDA official stated that UniQure must perform a placebo-controlled trial for its gene therapy, which is administered directly into the brain [2] - The FDA official disputed UniQure's claim that conducting such a study would be unethical due to the need for general anesthesia [2] - The FDA is facing scrutiny for recent rejections of drug approval applications, with companies alleging that the agency has reversed previous guidance [3] Group 2: UniQure's Response - UniQure has indicated that the requested type of study is not ethical, suggesting that it would pose significant risks to participants [2] - The FDA official implied that UniQure may be aware of the shortcomings of its previous trials and is not conducting the necessary clinical studies [3] - The ongoing conflict highlights a broader issue within the industry regarding regulatory expectations and the approval process for new therapies [3]

Group 1 - A senior FDA official labeled Uniqure's experimental Huntington's disease treatment as a "failed product," raising concerns about the future of its gene therapy [1] - The statement from the FDA official was made during a media conference call, indicating a significant setback for Uniqure [1] - This development adds to the uncertainty surrounding the efficacy and market potential of Uniqure's gene therapy for Huntington's disease [1]